In ₹ Crore except Per Share Latest Annual | JUBLPHARMA FY26 | GLAND FY26 | PPLPHARMA FY26 | KIMS FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 40.80× | 47.31× | — | 128.36× | 87.84× -54% | |
| P/B | ◆ 2.28× | 4.69× | 3.45× | 12.10× | 4.69× -51% | |
| EV/EBITDA | ◆ 14.42× | 27.91× | 35.05× | 42.56× | 35.05× -59% | |
| Market Cap | ₹16,211 Cr | ₹48,604 Cr | ₹28,134 Cr | ₹30,960 Cr | ₹30,960 Cr -48% | |
| Growth | ||||||
| Revenue CAGR 3Y | 9.64% | 21.06% | 7.79% | ◆ 21.12% | 21.06% -54% | |
| Revenue CAGR 5Y | 6.31% | 13.18% | — | ◆ 24.04% | 18.61% -66% | |
| Net Income CAGR 3Y | — | ◆ 9.57% | — | -12.87% | -1.65% | |
| Revenue YoY (latest Q) | 17.29% | 19.57% | 17.39% | ◆ 35.33% | 19.57% -12% | |
| Net Income YoY (latest Q) | -44.98% | ◆ 47.09% | 15.07% | -56.00% | 15.07% -398% | |
| Profitability | ||||||
| EBITDA Margin | 15.22% | ◆ 25.34% | 10.39% | 20.54% | 20.54% -26% | |
| Net Income Margin | 4.80% | ◆ 15.98% | -3.68% | 6.20% | 6.20% -23% | |
| Return on Common Equity | 5.62% | ◆ 9.92% | -3.99% | 9.44% | 9.44% -40% | |
| Return on Capital Employed | 6.31% | ◆ 11.06% | 0.68% | 7.96% | 7.96% -21% | |
| Return on Assets | 2.56% | ◆ 8.21% | -1.81% | 3.12% | 3.12% -18% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.45× | ◆ 0.02× | 0.67× | 1.27× | 0.67× -33% | |
| Interest Coverage | 3.87× | ◆ 36.24× | 0.27× | 2.56× | 2.56× +51% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹8,280 Cr | ₹6,431 Cr | ₹8,869 Cr | ₹3,905 Cr | ₹6,431 Cr +29% | |
| Net Income | ₹398 Cr | ₹1,027 Cr | −₹326 Cr | ₹242 Cr | ₹242 Cr +64% | |
| Total Assets | ₹15,523 Cr | ₹12,511 Cr | ₹17,965 Cr | ₹7,759 Cr | ₹12,511 Cr +24% | |
| EPS | ₹25.15 | ₹62.35 | ₹-2.46 | ₹6.03 | ₹6.03 +317% | |
| Book Value per Share | ₹449.09 | ₹628.67 | ₹61.5 | ₹63.96 | ₹63.96 +602% | |